CELLINK, A BICO company, has launched BIO CELLX, a novel system that automates 3D cell culture workflows by leveraging pre-validated protocols.
The BIO CELLX builds upon CELLINK’s bioprinting portfolio which utilises technologies. By introducing the concept of pre-validated protocols, the platform provides cell biologists a solution for the development of 3D models without need for coding, CAD modelling or parameter selection and optimistion.
“This product is an important step in proliferating 3D cell culture and the numerous advantages it can bring to cell biologists. With the BIO CELLX we have developed a solution that effectively empowers researchers to transition to 3D cell culture workflows, providing effective and reproducible models that can truly improve research outcomes,” said Johan Norrman, CTO, CELLINK.
“We are thrilled to be bringing the BIO CELLX to the drug discovery market. For the last five years, we have developed cutting edge bioprinters and have utilised this expertise to develop an automated biodispensing platform solution that makes the power of 3D accessible to all with easy to understand set up and effortless material and cell mixing. We look forward to enabling the pharma industry with technology which we hope will bring meaningful breakthroughs in cancer research and therapy development by providing biomimetic models,” added Cecilia Edebo, CEO, CELLINK.